Cytokinetics Sets New 12-Month Low at $3.84 (CYTK)
Cytokinetics (NASDAQ:CYTK)’s share price reached a new 52-week low on Thursday , American Banking and Market News reports. The stock traded as low as $3.84 and last traded at $3.88, with a volume of 376,292 shares changing hands. The stock had previously closed at $4.09.
Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Cytokinetics in a research note on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.60.
The stock has a 50-day moving average of $4.29 and a 200-day moving average of $6.34. The company’s market cap is $141.3 million.
Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, July 30th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.09. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $7.01 million. On average, analysts predict that Cytokinetics will post $-0.99 earnings per share for the current fiscal year.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.